Norditropin®

Ashton is 10 years old and loves planes. He draws them all the time, and he wants to design them when he grows up. Ashton was born with Noonan syndrome and is currently treated with Norditropin^®.

Dosing: 0.066 mg/kg/day is the recommended dose¹
Efficacy: 77% of children achieved normal height at year 3²

William is 4 years old. He was born with GHD and wants to be a pilot when he grows up. Willam is treated with Norditropin^®.

Dosing: 0.034 mg/kg/day¹
Efficacy: Average growth rate during the first year of treatment was 11.7 cm with the 0.034 mg/kg/day dose³

Gigi is seen here with her twin sister. The twins plan to open their own candy shop when they grow up.
Gigi was born SGA and is being treated with Norditropin^®.

Dosing: 0.035 mg/kg/day¹
Efficacy: 98% of the children reached an adult height within their target height range, and 85% reached a normal adult height.⁴

• Zero missed injections in a typical month^4,a
• 64% preferred this device to their current device³
• 92% of patients were more confident that Norditropin® had administered the correct GH dose³
• 96% of patients said they were ‘comfortable with the idea of future self-injection’ with Norditropin^®3

86% of patients reported that they would choose room temperature stability if given the choice^4,a

_{^a All Norditropin^® pens must be refrigerated (between 2°C and 8°C) prior to first use. After first opening: store for a maximum of 28 days at 2°C – 8°C. Alternatively, the medicinal product may be stored for a maximum of 21 days below 25°C. Do not freeze. Do not store close to any cooling elements.⁵}

Information, tools and resources for parents to help them better understand their child’s growth and development, which are important indicators of their overall health and wellbeing.

Living with a growth disorder can cause emotional distress, and the path to diagnosis can be challenging. Gain firsthand insights from patients and their families about life with a growth disorder.

RCP Norditropin^®.

Lee et al. Noonan syndrome and Turner syndrome patient respond similarly to 4 years’ growth-hormone-naive therapy: longitudinal analysis of growth-hormonenaive patients enrolled in the Nordinet^® international outcome study and the ANSWER program. Int J Pediatr Endocronol. 2015; 2015(1):17.

Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, Aristides Maniatis, Rasmus Juul Kildemoes, Jun Mori, Michel Polak, Rikke Beck Bang, Volker Böttcher, Stefano Stagi, Reiko Horikawa, Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial, The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 12, December 2022, Pages 3378–3388

Van Pareren et al. Adult Height after Long-Term, Continuous Growth Hormone (GH) Treatment in Short Children Born Small for Gestational Age: Results of a Randomized, Double-Blind, Dose-Response GH Trial. J Clin Endocrinol Metab.2003 Aug;88(8):3584-90.

Norditropin FlexPro Summary of Product Characteristics. November 2022.

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.

HQ24NORD00039, November 2024

For healthcare professionals only